The multi-biomarker blood test involves analyzing the risk for 8 major cancers (lung cancer, liver cancer,stomach cancer, colorectal cancer, prostate cancer, and breast cancer). By precisely measuring the peptidebiomarkers inside the blood and analyzing the data via big data statistics, the technology predicts the cancerrisk for individuals with high detectability rates.
It identifies cancer risks by comparing the biomarker values acquired by separating peptide from a smallamount of blood, with big data analysis numbers from more than 5,000 cases of normal and cancer-diagnosed samples.
To check someone’s health condition, we need an index with verifiable numbers. In medical terms, this index is called a ‘biomarker’ and BIOINFRA Life Science’s multi-biomarker blood test technology uses ‘peptide’ as a biomarker for analysis.
There exists an infinite number of micro-peptides inside the blood of our bodies. These are very important ‘biomarkers’ that reveal the status of our health because the number of these micro-peptides constantly changes depending on genetic factors and life patterns.
Extract a small amount of blood.
Conduct a precision analysis on the multiple peptide biomarkers inside the blood.
Analyze the results of precision analysis with BIOINFRA Life Science’s unique big data statistics.
Calculate the risk of each cancer through big data statistical analysis.
The multi-biomarker blood test was researched and developed for the 8 major cancers(lung cancer, liver cancer, stomach cancer, colorectal cancer, prostate cancer, breast cancer, pancreatic cancer, and ovarian cancer),and we are continuing our research for other cancers as well.
Multi-Biomarker Blood Test maintains a high level of specificity while returning more accurate testresults with a far greater level of sensitivity compared to existing blood tests.